Pharmaceutical care and its relationship to prescribing behaviour of general practitioners

Pharmacy World and Science

Volumn 28, Issue 5, 2006, Pages 302-308

  Muijrers, Paul E M ^a   Grol, Richard P T M ^b,c   Sijbrandij, Jildou ^b   Janknegt, Rob ^d   Knottnerus, J André ^e  

^a CZ Health Insurance Company   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^d Sittard Geleen Heerlen   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cooperation; General practitioner; Indicators; Pharmaceutical care; Pharmacist; Pharmacotherapy; Prescribing indicators; Prescribing quality; The Netherlands

Indexed keywords

ACETIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETAMETHASONE; BETAMETHASONE VALERATE; CAPTOPRIL; CHLORTALIDONE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FLUMETASONE PIVALATE; FLUOCINONIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE; HYDROCORTISONE BUTYRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAZOLE DERIVATIVE; METFORMIN; METOPROLOL; ORAL CONTRACEPTIVE AGENT; PROTON PUMP INHIBITOR; TOLBUTAMIDE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG;

ARTICLE; CLINICAL PHARMACY; COOPERATION; CORRELATION ANALYSIS; GENERAL PRACTITIONER; HUMAN; NETHERLANDS; PATIENT CARE; PATIENT COMPLIANCE; PHARMACIST ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION;

HUMANS; NETHERLANDS; PHARMACEUTICAL SERVICES; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; PRESCRIPTIONS, DRUG; QUESTIONNAIRES;

EID: 33845327059     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-006-9047-1     Document Type: Article

References (37)

1. Watkins C, Harvey I, Carthy P, Moore L, Robinson E, Brawn R. Attitudes and behaviour of general practitioners and their prescribing costs: a national cross sectional survey. Qual Saf Health Care 2003;12(1):29-34.
2. Mantyselka P, Ahonen R, Kumpusalo E, Takala J. Variability in prescribing for musculoskeletal pain in Finnish primary health care. Pharm World Sci 2001;(6):232-6.
3. Jones MI, Greenfield SM, Jowett S, Bradley CP, Seal R. Proton pump inhibitors: a study of GPs' prescribing. Fam Pract 2001;18(3):333-8.
4. Bjerrum L, Bergman U . Wide variation in the number of different drugs prescribed by general practitioners. A prescription database study. Scand J Prim Health Care 2000;18(2):94-8.
5. Bjerrum L, Sogaard J, Hallas J, Kragstrup J. Polypharmacy in general practice: differences between practitioners. Br J Gen Pract 1999;49(440):195-8.
6. Guillemot D, Carbon C, Vauzelle-Kervroedan F, Balkau B, Maison P, Bouvenot G, Eschwege E. Inappropriateness and variability of antibiotic prescription among French office-based physicians. J Clin Epidemiol 1998;51(1):61-8.
7. McBride JE, Pater JL, Dorland JL, Lam YM. Extent and variation of omeprazole prescribing in an elderly population of Ontario. Ann Pharmacother 1997;31(4):411-6.
8. Muijrers PEM, Janknegt R, Sijbrandij J, Grol RP, Knottnerus JA Prescribing indicators. Development and validation of guideline-based prescribing indicators asan instrument to measure the variation in the prescribing behaviour of general practitioners. Eur J Clin Pharmacol 2004;60(10):739-46.
9. Lawrence M, Olesen F. Indicators of quality in healthcare. Eur J Gen Pract 1997;3:103-8.
10. Van Mil JWF. Pharmaceutical care, the future of pharmacy. Theory, research and practice. (Dissertation). University of Groningen. The Netherlands; ISBN: 90-9013367-4, 1997.
11. Van der Heide H, Tinke JL. Facts and figures, cost development of pharmaceutical aid. The Hague, The Netherlands: Foundation for Pharmaceutical Statistics; 1999.
12. Van Mil JW, Dudok van Heel MC, Boersma M, Tromp TF. Interventions and documentation for drug-related problems in Dutch community pharmacies. Am J Health Syst Pharm 2001;58(15):1428-31.
13. De Gier JJ. The Electronic Pharmaceutical Dossier: an effective aid to documenting pharmaceutical care data. Pharm World Sci 1996;18(6):241-3.
14. Kirking DM, Thomas JW, Ascione FJ, Boyd EL. Detecting and preventing adverse drug interactions: the potential contribution of computers in pharmacies. Soc Sci Med 1986;22(1):1-8.
15. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47(3):533-43.
16. Hakansson A, Andersson H, Cars H, Melander A. Prescribing, prescription costs and adherence to formulary committee recommendations: long-term differences between physicians in public and private care. Eur J Clin Pharmacol 2001;57(1):65-70.
17. Kocken GA. Medication discussion groups in the Netherlands: five years of experience. Med Educ 1999;33(5):390-3.
18. Bradley CP, Taylor RJ, Blenkinsopp A. Primary care-opportunities and threats. Developing prescribing in primary care. BMJ 1997;314(7082):744-7.
19. Matheson C, Bond CM, Mollison J. Attitudinal factors associated with community pharmacists' involvement in services for drug misusers. Addiction 1999;94(9):1349-59.
20. Farris KB, Schopflocher DP. Between intention and behavior: an application of community pharmacists' assessment of pharmaceutical care. Soc Sci Med 1999;49(1):55-66.
21. Odedina FT, Hepler CD, Segal R, Miller D. The Pharmacists' Implementation of Pharmaceutical Care (PIPC) model. Pharm Res 1997;14(2):135-44.
22. Carroll NV. Do community pharmacists influence prescribing? J Am Pharm Assoc (Wash DC) 2003;43(5):612-21.
23. Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes (Cochrane Review). In: The Cochrane Library, vol. 4. Oxford; 2001.
24. Guidelines for ATC classification and DDD assignment. Oslo: World Health Organization Collaborating Centre for Drug Statistics Methodology. 2004. Available at: http://www.whocc.no/atcddd/indexdatabase/index.php. Accessed 1 february 2005..
25. Vektis BV. Externe integratie declaratie farmaceutische hulp. 1995 [External integration of declarations for pharmaceutical help]; available at http://www.vektis.nl/index.php. Accessed 1 February 2005.
26. Koninklijke Nederlandsche Maatschappij tot bevordering der Geneeskunst: Eisen en voorwaarden herregistratie huisartsen. [The Royal Dutch Medical Association: requirements and conditions for reregistration of general practitioners]. Staatscourant 2003;47:18.
27. Muijrers PEM, Knottnerus JA, Sijbrandij J, Janknegt R, Grol RPTM. Changing relationships: attitudes and opinions of general practitioners and pharmacists regarding the role of the community pharmacist. Pharm World Sci 2003;25(5):235-41.
28. Muijrers PEM, Knottnerus JA, Sijbrandij J, Janknegt R, Grol RPTM. Pharmacists in primary care. Determinants of the care-providing function of Dutch community pharmacists in primary care. Pharm World Sci 2004;26(5):256-62.
29. Olesen F, Vedsted P, Norskov Nielsen J. Change in ranking order of prescribing patterns by age and sex standardization of the practice population. Scand J Prim Health Care 1996;14(3):159-64.
30. Sellors J, Kaczorowski J, Sellors C, Dolovich L, Woodward C, Willan A et al. A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. Can Med Assoc J 2003;169(1):17-22.
31. Krska J, Cromarty JA, Arris F, Jamieson D, Hansford D, Duffus PR, Downie G, Seymour DG. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing 2001;30(3):205-11.
32. Bernsten C, Bjorkman I, Caramona M, Crealey G, Frokjaer B, Grundberger E, et al. Improving the well-being of elderly patients via community pharmacy-based provision of pharmaceutical care: a multicentre study in seven European countries. Drugs Aging 2001;18:63-77.
33. De Vries CS. Collaboration in healthcare. The tango to drug safety. Dissertation. University of Groningen. The Netherlands; 1998.
34. Hamley JH, MacGregor SH, Dunbar JA, Cromarty JA. Integrating clinical pharmacists into the primary health care team: a framework for rational and cost-effective prescribing. Scott Med J 1997;42(1):4-7.
35. Muijrers PEM, Knottnerus JA, Sijbrandij J, Janknegt R, Grol RPTM. Differences in prescribing between general practitioners. Impact of the cooperation with pharmacists and impact of visits from pharmaceutical industry representatives. Fam Pract (In press, accepted for publication June 29th 2005).
36. Van Dijk L, Barnhoorn H, De Bakker D. Het Farmacotherapie Overleg in 1999, stand van zaken en effecten op voorschrijven [The Pharmacotherapeutic audit meeting in 1999, current state of affairs and effects on prescribing]. Nivel, Utrecht, The Netherlands; 2001.
37. Nathan A, Sutters CA. A comparison of community pharmacists' and general practitioners' opinions on rational prescribing, formularies and other prescribing related issues. J R Soc Health1993;113:302-7.